The Fort Worth Press - Jaguar Health Family Company Napo Therapeutics Named “Best Pharmaceuticals Innovator of the Year - Europe”

USD -
AED 3.6725
AFN 64.498045
ALL 82.224051
AMD 357.911109
ANG 1.790403
AOA 917.999992
ARS 1552.245042
AUD 1.487498
AWG 1.8
AZN 1.701568
BAM 1.778889
BBD 2.013452
BDT 124.862431
BGN 1.77347
BHD 0.377187
BIF 3006.125762
BMD 1
BND 1.288366
BOB 11.661285
BRL 5.778103
BSD 0.999695
BTN 93.389482
BWP 13.993424
BYN 3.000114
BYR 19600
BZD 2.010633
CAD 1.430865
CDF 2294.000592
CHF 0.840555
CLF 0.025261
CLP 994.190035
CNY 6.66615
CNH 6.66805
COP 3309.02
CRC 445.311541
CUC 1
CUP 23.992906
CVE 100.292423
CZK 22.169932
DJF 178.024567
DKK 6.80141
DOP 60.539085
DZD 137.094024
EGP 53.720858
ERN 15
ETB 164.079674
EUR 0.90995
FJD 2.297898
FKP 0.756582
GBP 0.757725
GEL 2.590255
GGP 0.756582
GHS 11.730947
GIP 0.756582
GMD 74.000173
GNF 8857.115571
GTQ 7.640288
GYD 209.05242
HKD 7.845155
HNL 26.876953
HRK 6.831965
HTG 130.972791
HUF 333.799019
IDR 18254
ILS 3.254645
IMP 0.756582
INR 93.45245
IQD 1515.562185
IRR 1929053.503608
ISK 124.48026
JEP 0.756582
JMD 158.860526
JOD 0.709026
JPY 159.414008
KES 129.990105
KGS 87.449026
KHR 4078.347196
KMF 448.000085
KPW 900.00035
KRW 1329.397181
KWD 0.31169
KYD 0.833136
KZT 443.84516
LAK 22515.803356
LBP 89525.524706
LKR 332.648142
LRD 167.946083
LSL 16.912988
LTL 2.95274
LVL 0.60489
LYD 6.460474
MAD 9.977716
MDL 18.305023
MGA 4547.687046
MKD 56.015616
MMK 2099.387164
MNT 3606.75335
MOP 8.079605
MRU 40.508252
MUR 47.860043
MVR 15.433829
MWK 1733.487348
MXN 18.45096
MYR 4.098963
MZN 63.907732
NAD 16.912757
NGN 1350.869856
NIO 36.790956
NOK 9.637045
NPR 149.424033
NZD 1.82065
OMR 0.384524
PAB 0.999682
PEN 3.414253
PGK 4.497642
PHP 63.574997
PKR 276.397058
PLN 4.00875
PYG 6228.540504
QAR 3.644326
RON 4.867103
RSD 107.038986
RUB 82.204134
RWF 1479.544504
SAR 3.760904
SBD 8.137041
SCR 13.8922
SDG 601.498572
SEK 10.13571
SGD 1.289235
SHP 0.757117
SLE 22.801691
SLL 20969.503664
SOS 571.283045
SRD 37.437963
STD 20697.981008
STN 22.283565
SVC 8.747021
SYP 13002.000337
SZL 16.91126
THB 33.8665
TJS 9.212201
TMT 3.5
TND 3.02519
TOP 2.40776
TRY 50.441697
TTD 6.768777
TWD 32.958011
TZS 2650.003017
UAH 45.318338
UGX 4148.305798
UYU 40.61103
UZS 12014.188913
VES 915.501901
VND 25687
VUV 121.064676
WST 2.823281
XAF 596.887869
XAG 0.021752
XAU 0.0002631714
XCD 2.70255
XCG 1.801703
XDR 0.707052
XOF 596.887869
XPF 108.472418
YER 236.550078
ZAR 16.95717
ZMK 9001.196037
ZMW 20.479237
ZWL 321.999592
SSP 5928.707524
MXV 2.06991
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Jaguar Health Family Company Napo Therapeutics Named “Best Pharmaceuticals Innovator of the Year - Europe”
Jaguar Health Family Company Napo Therapeutics Named “Best Pharmaceuticals Innovator of the Year - Europe”

Jaguar Health Family Company Napo Therapeutics Named “Best Pharmaceuticals Innovator of the Year - Europe”

Established in Milan, Italy in 2021, Napo Therapeutics is focused on expanding access to crofelemer, Jaguar's novel oral plant-based prescription drug, in Europe for orphan and/or rare diseases

Text size:

Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that Jaguar family company Napo Therapeutics has been named "Best Pharmaceuticals Innovator of the Year - Europe" by The European, a quarterly business publication published by CP Media Global Ltd in London.

"We are very honored to receive this award," said Massimo Radaelli, PhD, Chief Executive Officer of Napo Therapeutics and President of Jaguar International, "as we continue to be laser-focused on our mission of expanding access to crofelemer in Europe for orphan and rare diseases."

In participation with Jaguar and Jaguar family company Napo Pharmaceuticals, Napo Therapeutics is supporting investigator-initiated proof-of-concept (POC) studies of crofelemer for the rare disease indications of microvillus inclusion disease (MVID) and short bowel syndrome (SBS) with intestinal failure in the US, EU, and Middle East/North Africa regions, with results expected by the end of 2024 and throughout 2025. Additionally, a phase 2 trial of crofelemer in adult SBS patients with intestinal failure is expected to initiate before the end of 2024, as is a phase 2 trial of crofelemer in pediatric MVID patients. In accordance with the guidelines of specific EU countries, published data from clinical investigations in such rare diseases could support early patient access to crofelemer for these debilitating conditions in those countries.

Some SBS patients are subject to intestinal failure, often requiring parenteral nutrition (PN) up to 7 days a week. Intestinal failure is associated with significant morbidity and mortality; and high medical expenses associated with PN. SBS patients with intestinal failure also have severe chronic diarrhea, and the associated sequelae from diarrhea, including significant dehydration, metabolic acidosis or alkalosis and malnutrition, and other secondary symptoms, and these symptoms emerge either early or late, and many times become life-threatening.

MVID, an ultrarare congenital diarrheal disorder, is a severe infantile disease characterized by diarrhea, malabsorption, and acid/base instability, requiring intensive parenteral support for nutritional and fluid management, and there are currently no approved drug treatments.

The European, throughout the last decade, has been celebrating achievement, innovation and excellence through its annual awards program. The aim is to give corporate organizations an insight into various achievements within a range of organizations and reward excellence in the global business community. Covering a broad spectrum of business affairs globally, including Energy, Banking and Finance, Foreign Direct Investment, Sustainability, ESG, Shipping, Aviation, Executive Education, Technology, Lifestyle and Business Travel, The European is intended for decision makers around the world and is available through a global distribution network in EMEA, LATAM, North America and Asia.

About Crofelemer

Crofelemer is a novel, oral plant-based prescription medicine purified from the red bark sap, also referred to as "dragon's blood," of the Croton lechleri tree in the Amazon Rainforest. Napo Pharmaceuticals has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for indigenous communities.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about:

Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Visit the Make Cancer Less Shitty patient advocacy program at makecancerlessshitty.com and on Bluesky, X, Facebook & Instagram

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that results of investigator-initiated proof-of-concept studies of crofelemer for SBS with intestinal failure and MVID will be available by the end of 2024 and throughout 2025, Jaguar's expectation that a phase 2 trial of crofelemer in adult SBS patients with intestinal failure and a phase 2 trial of crofelemer in pediatric MVID patients will initiate before the end of 2024, and Jaguar's expectation that, in accordance with the guidelines of specific EU countries, published data from such clinical investigations could support early patient access to crofelemer for SBS with intestinal failure or MVID. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:

[email protected]
Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

L.Holland--TFWP